Nrx pharmaceuticals (nasdaq:nrxp) receives notice from nasdaq that the company has demonstrated compliance with the bid price requirement

The nasdaq panel has determined to continue the listing of the company's securities on the nasdaq stock market and is closing this matter four upcoming milestones expected: data from trials in suicidal bipolar depression and chronic pain, nda filing for iv ketamine and distribution of shares of hope therapeutics to existing shareholders recent unanticipated achievements related to intravenous ketamine and complicated urinary tract infection/pyelonephritis radnor, pa. , april 18, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq:nrxp) ("nrx pharmaceuticals", "nrx", the "company"), a clinical-stage biopharmaceutical company, today announced that (the "company") has received confirmation from nasdaq that they have demonstrated compliance with the nasdaq bid price requirement in listing rule 5550(a)(2) and has determined to continue the listing of the company's securities on the nasdaq stock market and is closing this matter.
NRXP Ratings Summary
NRXP Quant Ranking